These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 1773023)
1. Effects of the recombinant human erythropoietin (rHuEPO) administration on hematologic parameters, red cell creatine and 2,3-diphosphoglycerate contents, in patients affected by end-stage renal disease. Ricci G; Masotti M; De Paoli Vitali E; Vedovato M; Bedani PL; Gilli P Biomed Pharmacother; 1991; 45(8):349-52. PubMed ID: 1773023 [TBL] [Abstract][Full Text] [Related]
3. Effects of exercise on haematologic parameters, serum iron, serum ferritin, red cell 2,3-diphosphoglycerate and creatine contents, and serum erythropoietin in long-distance runners during basal training. Ricci G; Masotti M; De Paoli Vitali E; Vedovato M; Zanotti G Acta Haematol; 1988; 80(2):95-8. PubMed ID: 3138878 [TBL] [Abstract][Full Text] [Related]
4. 2,3 diphosphoglycerate-haemoglobin binding in uraemic patients treated with erythropoietin. A 31P-nuclear magnetic resonance study. Monti JP; Brunet P; Baz M; Klinkmann H; Berland Y; Merzouk T; Elsen R; Crevat A Nephrol Dial Transplant; 1993; 8(3):223-6. PubMed ID: 8385288 [TBL] [Abstract][Full Text] [Related]
6. Effects of a mixed physical activity (biathlon) on haematologic parameters, red cell 2,3-DPG and creatine, serum erythropoietin, urinary enzymes and microalbumin. Ricci G; Masotti M; De Paoli Vitali E; Vedovato M; Zanotti G Eur J Haematol; 1990 Sep; 45(3):178-9. PubMed ID: 2226732 [No Abstract] [Full Text] [Related]
7. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lui SF; Law CB; Ting SM; Li P; Lai KN Clin Nephrol; 1991 Nov; 36(5):246-51. PubMed ID: 1752075 [TBL] [Abstract][Full Text] [Related]
8. Recombinant human erythropoietin treatment of anemia in renal transplant patients. Lezaic V; Djukanovic L; Pavlovic-Kentera V Ren Fail; 1995 Nov; 17(6):705-14. PubMed ID: 8771243 [TBL] [Abstract][Full Text] [Related]
9. Anemia of chronic renal failure: treatment with erythropoietin. Navarro M; Alonso A; Avilla JM; Espinosa L Child Nephrol Urol; 1991; 11(3):146-51. PubMed ID: 1777893 [TBL] [Abstract][Full Text] [Related]
10. Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose. Ribeiro S; Garrido P; Fernandes J; Vala H; Rocha-Pereira P; Costa E; Belo L; Reis F; Santos-Silva A Clin Exp Pharmacol Physiol; 2016 Mar; 43(3):343-54. PubMed ID: 26889660 [TBL] [Abstract][Full Text] [Related]
11. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis. Lai KN; Lui SF; Leung JC; Law E; Nicholls MG Nephron; 1991; 57(4):394-400. PubMed ID: 1828543 [TBL] [Abstract][Full Text] [Related]
12. Influence of erythropoietin treatment on 2,3-bisphosphoglycerate and O2-affinity of red blood cells in children with renal anemia. Rapoport I; Engelhardt I; Drung I; Holzhütter H; Schmidt G Biomed Biochim Acta; 1990; 49(2-3):S280-3. PubMed ID: 2386518 [TBL] [Abstract][Full Text] [Related]
13. The effects of maintenance recombinant human erythropoietin therapy on ambulatory blood pressure recordings: conventional, Doppler, and tissue Doppler echocardiographic parameters. Kirkpantur A; Kahraman S; Yilmaz R; Arici M; Altun B; Erdem Y; Yasavul U; Turgan C Artif Organs; 2005 Dec; 29(12):965-72. PubMed ID: 16305652 [TBL] [Abstract][Full Text] [Related]
14. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Herrera J; Nava M; Romero F; Rodríguez-Iturbe B Am J Kidney Dis; 2001 Apr; 37(4):750-7. PubMed ID: 11273875 [TBL] [Abstract][Full Text] [Related]
15. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Jungers P; Choukroun G; Oualim Z; Robino C; Nguyen AT; Man NK Nephrol Dial Transplant; 2001 Feb; 16(2):307-12. PubMed ID: 11158405 [TBL] [Abstract][Full Text] [Related]
16. Iron balance following recombinant human erythropoietin therapy for anemia associated with chronic renal failure. Hotta T; Ogawa H; Saito A; Ito A Int J Hematol; 1991 Jun; 54(3):195-200. PubMed ID: 1747454 [TBL] [Abstract][Full Text] [Related]
17. [Treatment of anemia in patients with chronic renal insufficiency undergoing hemodialysis with recombinant human erythropoietin: 12 months' experience]. de Sousa FT; Prata MM; Barbas JV; dos Santos JP Acta Med Port; 1990; 3(6):347-52. PubMed ID: 2089856 [TBL] [Abstract][Full Text] [Related]
18. Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet. Allegra V; Martimbianco L; Vasile A Nephrol Dial Transplant; 1997 May; 12(5):924-32. PubMed ID: 9175044 [TBL] [Abstract][Full Text] [Related]
19. The efficacy of erythropoietin in human immunodeficiency virus-infected end-stage renal disease patients treated by maintenance hemodialysis. Shrivastava D; Rao TK; Sinert R; Khurana E; Lundin AP; Friedman EA Am J Kidney Dis; 1995 Jun; 25(6):904-9. PubMed ID: 7771487 [TBL] [Abstract][Full Text] [Related]
20. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Carlini R; Obialo CI; Rothstein M Am J Hypertens; 1993 Feb; 6(2):103-7. PubMed ID: 8471228 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]